Save time and jump to the most important pieces.
Date | Price Target | Rating | Analyst |
---|---|---|---|
12/8/2023 | $3.00 | Buy | H.C. Wainwright |
9/25/2023 | $3.50 → $2.00 | Buy → Hold | Canaccord Genuity |
10/20/2021 | $13.00 | Buy | Canaccord Genuity |
8-K - Quantum-Si Inc (0001816431) (Filer)
8-K - Quantum-Si Inc (0001816431) (Filer)
8-K - Quantum-Si Inc (0001816431) (Filer)
Published Preprint Demonstrates Platinum's Capability to Discriminate Peptide Variants with Single Amino Acid Resolution Quantum-Si Incorporated (NASDAQ:QSI) ("Quantum-Si," "QSI" or the "Company"), The Protein Sequencing Company™, today announced a newly released preprint publication on BioRxiv, from Dr. Gloria Sheynkman at the University of Virginia School of Medicine. In the publication, Sheynkman and team demonstrate the application of Quantum-Si's Platinum™ single-molecule benchtop sequencer to distinguish proteoform-informative peptides within the human tropomyosin (TPM) gene family. This study highlights Platinum's ability to achieve single amino acid resolution, revealing variations
Quantum-Si Incorporated (NASDAQ:QSI) ("Quantum-Si," "QSI" or the "Company"), The Protein Sequencing Company™, today announced that it will be participating in two upcoming investment conferences. Jeff Hawkins, Quantum-Si's Chief Executive Officer, will participate in a fireside chat discussion at the UBS Global Healthcare Conference on Wednesday, November 13th, at 8:45 AM PT. On Thursday, November 21st at 8:00 AM ET, Mr. Hawkins will participate in a fireside chat discussion at the Canaccord Medtech, Diagnostics & Services Forum in New York City. A live and archived webcast of the event will be available in the "Investors" section of the Quantum-Si website under Events & Presentations.
Quantum-Si Incorporated (NASDAQ:QSI) ("Quantum-Si," "QSI" or the "Company"), The Protein Sequencing Company™, today announced that the Company will host an Investor & Analyst event in New York City on November 20th, 2024. Quantum-Si's management team will provide updates on the Company's evolving technology roadmap, emerging applications for protein sequencing and the expanding commercial opportunities that these innovations create. A live question and answer session will follow the formal presentations. EVENT DETAILS: WHEN: Wednesday, November 20, 2024 | 10AM – 12PM EST WHERE: Westin NY Times Square, 270 West 43rd Street, New York, NY, 10036 REGISTRATION LINK (both in-person & virtual*
Quantum-Si Incorporated (NASDAQ:QSI) ("Quantum-Si," "QSI" or the "Company"), The Protein Sequencing Company™, today announced the appointment of Charles ("Chuck") Kummeth to the role of independent Chairman of the Board, effective May 27, 2024. Mr. Kummeth has over 35 years of leadership experience in Life Sciences most recently as President and CEO of Bio-Techne. During Mr. Kummeth's tenure at Bio-Techne, he oversaw tremendous growth across all aspects of the business including annual revenue growth from $300M to over $1.1B, growth in the employee base from 800 to over 3,000, and the successful execution of 19 acquisitions, all while maintaining a 35% or better EBITDA level. Under Mr. Ku
Quantum-Si Incorporated (NASDAQ:QSI) ("Quantum-Si," "QSI" or the "Company"), The Protein Sequencing CompanyTM, today announced the appointment of Paula Dowdy, a senior executive with more than 35 years of experience across life sciences, enterprise software, and technology industries, to its Board of Directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240321183506/en/Paula Dowdy (Photo: Business Wire) Ms. Dowdy currently serves on the Board of Directors for SPT Labtech, a world leading lab automation tools company based in the UK and is an advisor at EQT Life Sciences, one of Europe's leading investors targeting innovative
Quantum-Si Incorporated (NASDAQ:QSI) ("Quantum-Si," "QSI" or the "Company"), The Protein Sequencing Company™, today announced that it has entered into an agreement with a new distributor who will make the company's protein sequencing instrument, Platinum® available for the first time in Japan. TOMY Digital Biology Co., Ltd., a renowned importer and distributor with a rich history dating back to the 1950s, will distribute Quantum-Si's next-generation protein sequencer™ and associated consumables throughout Japan. "Working with Quantum-Si marks a pivotal moment for TOMY Digital Biology, aligning with our commitment to advancing life sciences. We're poised to empower Japanese researchers wit
Quantum-Si Incorporated (NASDAQ:QSI) ("Quantum-Si," "QSI" or the "Company"), The Protein Sequencing CompanyTM, today announced that it will report financial results for the third quarter of 2024 on Tuesday, November 12, 2024. Company management will host a conference call to discuss financial results and provide a business update on the same day at 8:00 AM ET. Individuals interested in listening to the conference call may do so by joining the live webcast on the Investors section of the Quantum-Si website under Events and Presentations. Alternatively, individuals can register here to receive a dial-in number and personalized PIN to participate in the call. An archived webcast of the event
Announces Release of Version 3 Sequencing Kit Announces Two Additional Kit Launches Expected by End of 2024 Quantum-Si Incorporated (NASDAQ:QSI) ("Quantum-Si," "QSI" or the "Company"), The Protein Sequencing Company™, today announced financial results for the second quarter ended June 30, 2024. Press Release Highlights Reported revenue of $622,000 in the second quarter of 2024 Completed the first quarter of full commercial launch of the Platinum® instrument in Q2 2024 Announces the launch of the version 3 sequencing kit Announced appointment of Chuck Kummeth as independent Chairman of the Board of Directors Expect to l
Quantum-Si Incorporated (NASDAQ:QSI) ("Quantum-Si," "QSI" or the "Company"), The Protein Sequencing CompanyTM, today announced that it will report financial results for the second quarter of 2024 on Wednesday, August 7, 2024. Company management will host a conference call to discuss financial results and provide a business update on the same day at 4:30 PM ET. Individuals interested in listening to the conference call may do so by joining the live webcast on the Investors section of the Quantum-Si website under Events and Presentations. Alternatively, individuals can register here to receive a dial-in number and personalized PIN to participate in the call. An archived webcast of the eve
4 - Quantum-Si Inc (0001816431) (Issuer)
4 - Quantum-Si Inc (0001816431) (Issuer)
4 - Quantum-Si Inc (0001816431) (Issuer)
SC 13D/A - Quantum-Si Inc (0001816431) (Subject)
SC 13G/A - Quantum-Si Inc (0001816431) (Subject)
SC 13G - Quantum-Si Inc (0001816431) (Subject)
H.C. Wainwright initiated coverage of Quantum-Si with a rating of Buy and set a new price target of $3.00
Canaccord Genuity downgraded Quantum-Si from Buy to Hold and set a new price target of $2.00 from $3.50 previously
Canaccord Genuity initiated coverage of Quantum-Si with a rating of Buy and set a new price target of $13.00
Quantum-Si Incorporated (NASDAQ:QSI) ("Quantum-Si," "QSI" or the "Company"), The Protein Sequencing Company™, today announced a presentation by Gloria Sheynkman, Ph.D., Assistant Professor in the Department of Molecular Physiology and Biological Physics at the University of Virginia at the Festival of Genomics and Biodata conference being held in Boston on June 12-13, 2024.The presentation, titled "Next Generation Proteomics to Detect Disease-Relevant Proteoforms" will be on Wednesday, June 12th at 2:50 p.m. on the Omics Stage and will describe the application of Quantum-Si's Next-Generation Protein Sequencing ("NGPS") to identify protein variants that have a role in complex disease.
Quantum-Si Incorporated (NASDAQ:QSI) ("Quantum-Si," "QSI" or the "Company"), The Protein Sequencing Company™, today announced the appointment of Charles ("Chuck") Kummeth to the role of independent Chairman of the Board, effective May 27, 2024.Mr. Kummeth has over 35 years of leadership experience in Life Sciences most recently as President and CEO of Bio-Techne. During Mr. Kummeth's tenure at Bio-Techne, he oversaw tremendous growth across all aspects of the business including annual revenue growth from $300M to over $1.1B, growth in the employee base from 800 to over 3,000, and the successful execution of 19 acquisitions, all while maintaining a 35% or better EBITDA level. Under Mr. Kummet
HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Quantum-Si (NASDAQ:QSI) with a Buy and maintains $4 price target.
4 - Quantum-Si Inc (0001816431) (Issuer)
4 - Quantum-Si Inc (0001816431) (Issuer)
3 - Quantum-Si Inc (0001816431) (Issuer)